Kringle Pharma, Inc.

2026/11/18 20:31 Updated
Market Cap: $26.6M (¥4.2B)
Stock Price: $3.29 (¥525)
Exchange Rate: 1 USD = ¥159.49

Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision)

Decided on third-party allotment of new shares (567,100 shares and allocation of 567,100 shares + 378,000 shares to Maruishi Pharmaceutical and Xenoac HD respectively) and issuance of stock acquisition rights (total 21,460 units; 19th series exercise price 270 yen, 20th series 235 yen). Raising total funds of approximately 2,206 million yen (net proceeds), with main uses including preparation for a Phase III clinical trial in the U.S. for acute spinal cord injury, establishment of manufacturing system for recombinant human HGF protein active pharmaceutical ingredient, domestic API manufacturing, and working capital. Maximum dilution is about 35.97%.

Importance:
Page Updated: November 18, 2026
IR Disclosure Date: November 18, 2026

Key Figures

  • Total funds raised: 2,222,176,550 yen → Estimated net proceeds 2,206,176,550 yen
  • Total number of shares offered: 945,100 shares
  • Total number of stock acquisition rights: 21,460 units
  • Allotment recipients: Maruishi Pharmaceutical 567,100 shares, Xenoac HD 378,000 shares
  • Dilution rate: Maximum approx. 35.97%

AI要約

Overview of Capital Policy

Kringle Pharma, Inc. has resolved to issue new shares by third-party allotment and to issue the 19th and 20th series of stock acquisition rights. The allotment recipients are Maruishi Pharmaceutical Co., Ltd. and Xenoac Holdings Co., Ltd., to be allotted 567,100 shares and 378,000 shares respectively. The stock acquisition rights total 21,460 units (10,730 units each), with subscription prices of 270 yen for the 19th series and 235 yen for the 20th series. Total funds amount to approximately 2,216 million yen, and the use of proceeds includes expenses to advance preparation for a Phase III trial in the U.S. for acute spinal cord injury, establishment of manufacturing capacity for recombinant human HGF protein active pharmaceutical ingredient, domestic API manufacturing, and working capital.

Impact on Shareholders and Outlook

Dilution is expected to be up to approximately 35.97%, and a third-party committee reviewed the reasonableness following exchange deliberations. The use of proceeds aims to accelerate growth strategy and target future enhancement of corporate value. Exercise price adjustment mechanisms and floors are set under certain conditions to appropriately manage shareholder impact. Following the implementation of the capital policy, attention should be paid to changes in shareholding ratios of Maruishi Pharmaceutical and Xenoac HD and movements of major shareholders.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Kringle Pharma, Inc.

Company overview · Stock price · Financial data · All IR

View company page →